Connecticut is currently home to 1248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
NCT04398628
Recruiting
In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN) clinical studies, the number of new therapies for all congenital and acquired hematologic conditions, not just those for bleeding and clotting disorders, is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have yet to demonstrate long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/26/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
Register for Updates
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883
Recruiting
To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/26/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Register for Updates
Investigating the Mu:Kappa Opioid Receptor Imbalance in Alcohol Use Disorder
NCT05957159
Recruiting
The primary objective of this multimodal positron emission tomography (PET) study is to use PET brain imaging to measure both MOR (Mu-Opioid receptors) and KOR (kappa-opioid receptors) in participants with alcohol use disorder (AUD) and to quantify the relationships between MOR and KOR, separately and jointly, to key clinical outcomes (e.g., craving, mood, withdrawal, time to lapse) during a quit attempt.
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
03/25/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Alcohol Use Disorder
Register for Updates
Empagliflozin in Patients With Cirrhosis and Ascites
NCT05726032
Recruiting
A proof-of-concept placebo-controlled trial to explore the acute and 14-day effects of empagliflozin on natriuresis and total body water in patients with cirrhosis and ascites. We will additionally investigate its effect on neurohumoral activation, and renal hemodynamics.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Cirrhosis, Liver Failure
Register for Updates
Brain-Training Treatment for Long COVID in Older Adults
NCT05705193
Recruiting
This research is being done to collect preliminary data on the potential of computerized "brain-training" exercises for treating Long COVID symptoms in older adults. The investigators hypothesize that computerized brain-training will be an acceptable and feasible intervention for treating Long COVID symptoms in older adults. The investigators also expect to provide initial evidence that computerized brain-training has potential for improving thinking, mood, and other aspects of everyday function... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
03/25/2025
Locations: UConn Health, Farmington, Connecticut
Conditions: Post-Acute COVID-19 Syndrome
Register for Updates
Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
NCT05629208
Recruiting
The goal of this clinical study is to test how edecesertib (formerly known as GS-5718) can be useful in treating Cutaneous Lupus Erythematosus (CLE) in participants with CLE. Information on what is happening in the body relating to CLE, how the body processes, is affected by and responds to the study drug, and any study drug side effects will also be collected in this study.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/25/2025
Locations: Yale Center for Clinical Investigation (YCCI), New Haven, Connecticut
Conditions: Cutaneous Lupus Erythematosus (CLE)
Register for Updates
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
NCT05576350
Recruiting
Ecological momentary interventions (EMI), which use phones to deliver messages to reduce alcohol use and related risk behaviors during or prior to drinking events, can help to address triggers in real-time. GPS tracking can determine when individuals visit places they have previously reported drinking or triggers to drink and then EMI messages can be delivered upon arrival to prevent risky alcohol use. A mobile app has been developed that uses GPS tracking to determine when individuals visit "ri... Read More
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
03/25/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Risk Behavior, Alcohol Use Disorder, HIV Infections
Register for Updates
Phase 2 Trial of Voyager V1 in Combination with Cemiplimab in Cancer Patients
NCT04291105
Recruiting
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
Register for Updates
Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
NCT05669534
Recruiting
The investigators will conduct an optimization trial among N=256 PWID newly started on medication for opioid use disorder and Pre-Exposure Prophylaxis (PrEP) to assess the performance of four intervention components (Attention, Executive Functioning, Memory, and Information Processing) aimed at enhancing the ability of PWID on MOUD to process and utilize HIV prevention content, leading to improvements in HIV prevention information, motivation, behavioral skills, and behaviors (IMB).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: APT Foundation, New Haven, Connecticut
Conditions: Hiv, Opioid Use Disorder
Register for Updates
Study of INCB123667 in Subjects With Advanced Solid Tumors
NCT05238922
Recruiting
This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapies in participants with selected advanced or metastatic solid tumors. This study will consist of 2 parts. In Part 1, INCB123667 will be administered as monotherapy and in Part 2, INCB123667 will be administered in combination with anticancer therapies of intere... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Solid Tumors
Register for Updates
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
NCT03821129
Recruiting
This study will assess the safety and effectiveness of GORE® CARDIOFORM Septal Occluder in a post approval setting and evaluate the quality of operator education and training and transferability of trial experience to a post-market setting.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/24/2025
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Stroke, PFO - Patent Foramen Ovale
Register for Updates
A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)
NCT05095727
Recruiting
The main goal of this trial is to evaluate the safety and tolerability of mRNA-3745 via intravenous (IV) administration in adult and pediatric participants with GSD1a.
Gender:
ALL
Ages:
6 years and above
Trial Updated:
03/22/2025
Locations: University of Connecticut Health Center, Farmington, Connecticut
Conditions: Glycogen Storage Disease
Register for Updates